Analysis of drug resistance of second-line anti-TBdrugs to baseline strain in patients with multidrug-resistant pulmonary tuberculosis
- VernacularTitle:耐多药肺结核患者基线菌株二线抗结核药物耐药情况分析
- Author:
Guiqing HE
1
;
Jichan SHI
;
Lianpeng WU
;
Xiangao JIANG
Author Information
1. 浙江省温州市中心医院感染科
- Keywords:
Mycobacterium;
Tuberculosis;
Second-line drugs;
Drug susceptibility testing;
Multidrug-resistant tuberculosis
- From:
China Modern Doctor
2018;56(15):84-87
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the resistance of second-line anti-TBdrugs to baseline strain in patients with multidrug-resistant pulmonary tuberculosis. Methods Atotal of 52 baseline strains in patients with multidrug-resistant pulmonary tuberculosis collected from March 2016 to May 2017 in our hospital were randomly selected. The sensitivity of the nine kinds of second-line anti-TBdrugs was tested, to analyze the proportion of different drug resistance and cross-resistance of similar drugs. Results Among the 9 second-line anti-TBdrugs, the ratio of drug resistance was ofloxacin =levofloxacin(59. 6％, 31/52)＞moxifloxacin(30. 8％, 16/52)＞ amikacin=kanamycin(both 9. 6％,5/52)＞paminosalicylic acid=cycloserine(both 7. 7％, 4/52)＞ capreomycin =prothionamide(both 9. 6％, 3/52). Ofloxacin was completely cross-resistant with levofloxacin, and its cross-resistant rate with moxifloxacin accounted for 51. 6％ (15/31). Amikacin was completely cross-resistant with kanamycin, and its cross-resistant rate with capreomycin accounted for 60％. Conclusion The baseline strains of patients with multi-drug resistant pulmonary tuberculosis are seriously resistant to fluoroquinolones. There is resistance to some extent for other second-line anti-tuberculosis drugs. Therefore, second-line drug susceptibility testing should be completed prior to establishing an effective MDR-TBtreatment regimen.
